Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.

The Journal of clinical investigation - 1 Feb 2024

Wu Muzhou, Hanly Ailish, Gibson Frederick, Fisher Robert, Rogers Samantha, Park Kihyun, Zuger Angelina, Kuang Kevin, Kalin Jay H, Nocco Sarah, Cole Matthew, Xiao Amy, Agus Filisia, Labadorf Adam, Beck Samuel, Collard Marianne, Cole Philip A, Alani Rhoda M

Abstract excerpt

Virtually all patients with BRAF-mutant melanoma develop resistance to MAPK inhibitors largely through nonmutational events. Although the epigenetic landscape is shown to be altered in therapy-resistant melanomas and other cancers, a specific targetable epigenetic mechanism has not been validated. Here, we evaluated the corepressor for element 1-silencing transcription factor (CoREST) epigenetic repressor complex...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Line, Tumor
Share to Co-Repressor Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Melanoma

Share to p38 Mitogen-Activated Protein Kinases

Share to Phenotype

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Source

Open in PubMed Open full text

Identifiers

PMID: 38300709
DOI: 10.1172/JCI171063
PMCID: PMC10940100

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The CoREST repressor complex mediates phenotype switching and therapy resistance in melanoma.PMID 38300709Read ↗

The CoREST Repressor Complex Mediates Phenotype Switching and Therapy Resistance in MelanomaSemantic proximity Read ↗

A TCF4/BRD4-dependent regulatory network confers cross-resistance to targeted and immune checkpoint therapy in melanomaSemantic proximity Read ↗

Enhancer Reprogramming in Melanoma Immune Checkpoint Therapy ResistanceSemantic proximity Read ↗

Mapping convergent regulators of melanoma drug resistance by PerturbFate.Semantic proximity Read ↗

Specific <i>SOX10</i> enhancer elements modulate phenotype plasticity and drug resistance in melanomaSemantic proximity Read ↗

Epigenetic Mechanisms Underlying Melanoma Resistance to Immune and Targeted TherapiesSemantic proximity Read ↗

Divergent BRAF Inhibitor Resistance Mechanisms Revealed through Epigenetic Mapping.Semantic proximity Read ↗

Recurrent Tumor Cell-Intrinsic and -Extrinsic Alterations during MAPKi-Induced Melanoma Regression and Early Adaptation.Semantic proximity Read ↗

Decitabine reverses innate immune gene suppression in rare melanomasSemantic proximity Read ↗

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaSemantic proximity Read ↗

Loss of CITED1, an MITF regulator, drives a phenotype switch in vitro and can predict clinical outcome in primary melanoma tumoursSemantic proximity Read ↗

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling PathwaysSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.